ProShare Advisors LLC Acquires 8,491 Shares of Edwards Lifesciences Co. (NYSE:EW)

ProShare Advisors LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 10.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 90,668 shares of the medical research company's stock after acquiring an additional 8,491 shares during the quarter. ProShare Advisors LLC's holdings in Edwards Lifesciences were worth $6,712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $30,000. Catalyst Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $54,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $62,000. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. Citigroup reiterated a "buy" rating and issued a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday. Truist Financial cut their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $80.20.

Insider Activity

In related news, VP Daveen Chopra sold 1,500 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the transaction, the vice president now owns 33,496 shares in the company, valued at $2,514,879.68. This represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the transaction, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,150,791.86. This trade represents a 27.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 67,692 shares of company stock worth $4,822,074 over the last 90 days. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Up 0.3%

Shares of NYSE:EW traded up $0.19 on Friday, hitting $74.98. 3,738,140 shares of the company traded hands, compared to its average volume of 5,152,364. The stock has a 50 day simple moving average of $72.78 and a 200-day simple moving average of $72.09. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $43.98 billion, a PE ratio of 10.76, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business earned $0.66 EPS. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.